Gynecological Cancers Therapeutics Market Size and Forecast 2035
The global gynecological cancers therapeutics market is estimated at USD 18.40 billion in 2025 and is forecast to reach USD 37.57 billion by 2035, expanding at a CAGR of 7.4%.
The contemporary market is substantially broader. Endometrial cancer now has several first-line checkpoint-inhibitor combinations; ovarian cancer has PARP maintenance, FRα-directed ADC therapy, KRAS-selected RAF/MEK-FAK pathway treatment, PD-L1-selected pembrolizumab and a newly approved glucocorticoid-receptor antagonist regimen; and cervical cancer incorporates pembrolizumab during definitive chemoradiation as well as tissue-factor-directed ADC therapy in recurrent disease.
Gynecological Cancers Therapeutics Market Highlights
- 2025 Market Size: USD 18.40 Billion
- 2035 Forecast: USD 37.57 Billion
- CAGR, 2026-2035: 7.4%
- Largest Region: North America - 42.4% share
- Fastest-Growing Region: Asia-Pacific
- Largest Cancer Segment: Ovarian/Fallopian/Primary Peritoneal Cancer - 41.5%
- Largest Therapy Segment: Targeted Therapy & ADCs - 36.8%
- Fastest-Growing Modality: Antibody-Drug Conjugates and biomarker-selected immunotherapy
Gynecological Cancers Therapeutics Market Definition
Gynecological cancers are malignancies arising in the female reproductive tract and related tissues. The major therapeutic markets include ovarian, fallopian tube and primary peritoneal cancer; endometrial or uterine cancer; cervical cancer; vulvar cancer; vaginal cancer; and selected uterine sarcomas.
The category is increasingly defined by molecular biology rather than anatomical site alone.
Ovarian treatment can depend on BRCA mutation, homologous recombination deficiency, folate receptor alpha expression, PD-L1 status, and KRAS mutations. NCI identifies PARP inhibitors such as olaparib and niraparib as established maintenance options in selected ovarian cancer populations.
Endometrial treatment increasingly depends on mismatch repair and microsatellite-instability status, while modern molecular classification also distinguishes POLE-mutated, MMR-deficient, p53-abnormal, and no-specific-molecular-profile disease.
Cervical treatment is increasingly differentiated by disease stage and PD-L1 biology, with pembrolizumab incorporated into locally advanced chemoradiotherapy and advanced systemic treatment.
This makes gynecological oncology one of the clearest examples of a market moving from organ-based chemotherapy toward biomarker-directed treatment architecture.
White-Space Opportunity: From Biomarker Testing to Therapy Routing
The most attractive strategic opportunity is no longer simply discovering another broadly active cytotoxic medicine.
It is building a therapy-routing system around biomarkers.
A newly diagnosed or recurrent gynecological cancer can increasingly be evaluated through a sequence such as:
histology → stage → MMR/MSI → BRCA/HRD → PD-L1 → FRα → KRAS/HER2 and other actionable markers → treatment selection.
The economic importance is significant because each positive test can route a patient into a materially different treatment class.
In ovarian cancer, FRα testing identifies candidates for mirvetuximab soravtansine. FDA's full approval requires FRα-positive disease identified through an approved test.
KRAS mutation now identifies a subset of recurrent low-grade serous ovarian cancer eligible for avutometinib plus defactinib. FDA granted accelerated approval in May 2025 after RAMP-201 produced a 44% response rate.
PD-L1 became another ovarian-treatment selection biomarker in February 2026 when FDA approved pembrolizumab plus paclitaxel, with or without bevacizumab, for previously treated platinum-resistant disease with CPS ≥1.
Endometrial cancer has moved even further toward molecular segmentation, with checkpoint therapy increasingly built around MMR status and first-line treatment.
The market opportunity therefore extends beyond the drug itself into companion diagnostics, pathology workflow, molecular testing and treatment sequencing.
Gynecological Cancers Therapeutics Market Strategic Takeaways
The market is no longer appropriately described as chemotherapy-led. The current DMI page still says chemotherapy holds the largest share, but the commercial structure has moved toward high-value targeted therapies, PARP maintenance, checkpoint inhibitors, and ADCs.
Targeted therapies and ADCs are estimated to account for 36.8% of 2025 revenue, driven by PARP inhibitors, anti-VEGF treatment, lenvatinib, Elahere, Tivdak, and newer biomarker-directed therapies.
Immunotherapy is estimated at 28.6% and is gaining the fastest across endometrial and cervical cancers while entering selected ovarian cancer populations.
Endometrial cancer has experienced one of the largest treatment shifts. FDA expanded dostarlimab plus carboplatin/paclitaxel to the overall primary advanced or recurrent endometrial cancer population in August 2024, while pembrolizumab plus carboplatin/paclitaxel also has a first-line advanced/recurrent indication.
Ovarian cancer has become one of the most diverse gynecological therapeutic markets, spanning platinum therapy, PARP maintenance, anti-VEGF treatment, FRα ADCs, PD-1 therapy, KRAS-selected kinase therapy, and the newly approved relacorilant regimen.
Market Trends
Endometrial Cancer Has Become an Immunotherapy-First Market
The first-line advanced or recurrent endometrial cancer market has changed dramatically.
FDA expanded Jemperli/dostarlimab plus carboplatin and paclitaxel to adults with primary advanced or recurrent endometrial cancer in August 2024. In RUBY, median overall survival was 44.6 months with dostarlimab-containing treatment versus 28.2 months with chemotherapy alone.
Pembrolizumab similarly has an approved first-line advanced/recurrent endometrial regimen in combination with carboplatin and paclitaxel followed by pembrolizumab maintenance.
The next disruption could be chemotherapy-free first-line treatment in dMMR disease.
In July 2026, Merck announced that first-line pembrolizumab monotherapy significantly improved progression-free survival versus platinum-doublet chemotherapy in advanced or recurrent dMMR endometrial cancer. Regulatory submissions are expected to follow the Phase III results.
If approved, this could divide first-line endometrial cancer into increasingly distinct dMMR chemo-free and pMMR combination-treatment markets.
Endometrial ADCs Are Moving Rapidly Toward Late-Stage Development
Antibody-drug conjugates represent the largest pipeline white space in endometrial cancer.
In May 2026, Merck announced that sacituzumab tirumotecan, or sac-TMT, met both overall-survival and progression-free-survival endpoints versus chemotherapy in Phase III TroFuse-005 for advanced or recurrent endometrial cancer after platinum chemotherapy and prior PD-1/L1 therapy.
Merck is simultaneously conducting the Phase III TroFuse-033 study in first-line maintenance for mismatch-repair-proficient endometrial cancer, comparing pembrolizumab plus sac-TMT against pembrolizumab alone after induction chemotherapy. The study remained recruiting following its August 3, 2026 update.
GSK is developing another differentiated ADC, mocertatug rezetecan, targeting B7-H4. In April 2026, GSK reported a 67% confirmed response rate in a small advanced/recurrent endometrial cohort from BEHOLD-1 and announced five pivotal Phase III programs across ovarian and endometrial cancer.
The strategic race is therefore moving beyond whether ADCs work in gynecological cancer toward which antigen-FRα, TROP2, B7-H4, or others-best maps to each patient population and treatment line.
Ovarian Immunotherapy Finally Has a Biomarker-Selected Approval
Checkpoint inhibition historically produced less consistent results in unselected ovarian cancer than in endometrial cancer.
That changed on February 10, 2026.
FDA approved pembrolizumab plus paclitaxel, with or without bevacizumab, for previously treated platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer with PD-L1 CPS ≥1.
Among PD-L1-positive patients in KEYNOTE-B96, median overall survival was 18.2 months with pembrolizumab-containing treatment versus 14.0 months with control, and median PFS was 8.3 versus 7.2 months.
This creates an important new commercial segment because PD-L1 testing now directly affects ovarian treatment selection.
Relacorilant Creates a New Mechanism in Platinum-Resistant Ovarian Cancer
On March 25, 2026, FDA approved relacorilant/Lifyorli plus nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer after one to three prior regimens including bevacizumab.
Relacorilant is a glucocorticoid-receptor antagonist rather than another conventional DNA-damaging or antiangiogenic medicine.
In ROSELLA, median overall survival reached 16 months with relacorilant plus nab-paclitaxel versus 11.9 months with nab-paclitaxel alone.
The approval diversifies an ovarian treatment landscape previously dominated by chemotherapy, PARP inhibitors, anti-VEGF therapy, and ADCs.
FRα Is Becoming a Commercially Validated Ovarian Biomarker
Elahere/mirvetuximab soravtansine was converted to full FDA approval in March 2024 for FRα-positive platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after one to three prior treatment regimens.
The commercial franchise is already meaningful: AbbVie reported USD 690 million in global Elahere revenue during 2025.
Development is moving earlier.
At SGO 2026, AbbVie reported a 62.7% response rate with Elahere plus carboplatin followed by Elahere continuation therapy in FRα-expressing platinum-sensitive recurrent ovarian cancer.
The next commercial opportunity is therefore moving FRα ADC therapy from platinum-resistant disease into platinum-sensitive and potentially earlier maintenance settings.
KRAS Testing Has Created a New Low-Grade Serous Ovarian Segment
Low-grade serous ovarian carcinoma is biologically distinct from the far more common high-grade serous disease.
On May 8, 2025, FDA granted accelerated approval to avutometinib plus defactinib for KRAS-mutated recurrent LGSOC after previous systemic treatment.
RAMP-201 produced a confirmed 44% objective response rate in the KRAS-mutated population.
This creates a commercially important precedent: ovarian cancer treatment increasingly requires histology-specific and mutation-specific segmentation, rather than applying a single epithelial ovarian treatment pathway to every patient.
PARP Maintenance Remains Important but Is More Selective
PARP inhibitors remain a foundational ovarian cancer treatment class.
NCI continues to list olaparib and niraparib among maintenance treatments in appropriate ovarian, fallopian tube, and primary peritoneal cancer populations.
However, the market is becoming more selective.
Later-line PARP monotherapy indications have previously been withdrawn or narrowed following survival concerns, while the greatest clinical value remains concentrated in maintenance settings and biomarker-defined populations such as BRCA-mutated or homologous-recombination-deficient tumors.
This means future growth in ovarian cancer may increasingly come from ADCs, immunotherapy and novel combinations rather than simply expanding PARP exposure to broader unselected populations.
Cervical Cancer Immunotherapy Has Moved Into Curative-Intent Treatment
Cervical cancer immunotherapy is no longer confined to metastatic disease.
FDA approved pembrolizumab with definitive chemoradiotherapy in January 2024 for FIGO 2014 stage III-IVA cervical cancer. KEYNOTE-A18 incorporated pembrolizumab during cisplatin-based radiation followed by maintenance pembrolizumab.
That creates a materially larger commercial opportunity than later-line metastatic therapy because treatment is delivered during the curative-intent phase.
NCI continues to describe cisplatin-based chemoradiation as a central cervical treatment standard, now supplemented by immunotherapy in appropriate patients.
Tivdak Validated the Cervical ADC Market
FDA granted full approval to Tivdak/tisotumab vedotin in April 2024 for recurrent or metastatic cervical cancer progressing on or after chemotherapy.
The Phase III innovaTV 301 study demonstrated an overall-survival advantage over investigator-selected chemotherapy, making Tivdak an established post-chemotherapy ADC rather than merely an accelerated-approval product.
Merck's wider sac-TMT development program is also evaluating the TROP2-directed ADC in both second-line recurrent/metastatic cervical cancer and first-line cervical maintenance combinations, illustrating how rapidly ADC competition is expanding across gynecological tumors.
Gynecological Cancers Therapeutics Market Scope
| Metrics | Details |
| Historical Years | 2023-2024 |
| Base Year | 2025 |
| 2025 Market Size | USD 18.40 Billion - DMI Estimate |
| Forecast Period | 2026-2035 |
| 2035 Forecast | USD 37.57 Billion |
| CAGR | 7.40% |
| Largest Region | North America |
| Fastest-Growing Region | Asia-Pacific |
| Cancer Type | Ovarian/Fallopian/Peritoneal, Endometrial/Uterine, Cervical, Vulvar/Vaginal, Uterine Sarcoma & Others |
| Therapy | Targeted Therapy & ADCs, Immunotherapy, Chemotherapy, Hormonal Therapy, Others |
| Biomarkers | BRCA/HRD, MMR/MSI, PD-L1, FRα, KRAS, HER2, Others |
| End Users | Hospitals/Cancer Centers, Specialty Oncology Clinics, Outpatient/Other |
| North America | U.S., Canada, Mexico |
| Europe | Germany, UK, France, Italy, Spain, Rest of Europe |
| Asia-Pacific | China, Japan, India, South Korea, Australia, Rest of APAC |
| Latin America | Brazil, Argentina, Rest of Latin America |
| Middle East & Africa | Saudi Arabia, UAE, Israel, South Africa, Rest of MEA |
| Revenue Units | USD Billion |
| Report Insights | Market Size, Forecast, Molecular Segmentation, PARP, Immunotherapy, ADCs, Companion Diagnostics, Regional Analysis, Pipeline & Competitive Landscape |
Market Dynamics
Disease Burden Remains Substantial
Gynecological cancers collectively represent a major global oncology burden.
Endometrial cancer is the most common gynecological malignancy in the United States, and molecular features such as MMR deficiency, POLE mutation, and p53 abnormality now influence contemporary disease classification and treatment.
Cervical cancer remains especially important in lower-resource health systems. WHO continues to identify high-risk HPV as its primary cause and emphasizes substantial inequity in access to vaccination, screening and treatment.
These geographic differences mean pharmaceutical revenue is not proportional to disease incidence. Regions with the highest cervical cancer burden often have lower per-patient oncology expenditure than North America or Western Europe.
Longer Maintenance Treatment Increases Revenue per Patient
Modern gynecological oncology increasingly includes prolonged maintenance therapy.
PARP inhibitors can continue after platinum response, checkpoint inhibitors can continue after chemotherapy induction, and several emerging ADC programs are explicitly being developed as maintenance therapies.
This shifts the commercial model from short cycles of chemotherapy toward treatment lasting months or years.
Companion Diagnostics Are Becoming Mandatory Commercial Infrastructure
The market increasingly depends on testing before drug selection.
Elahere requires FRα testing. Pembrolizumab's new ovarian indication requires PD-L1 CPS testing. Avutometinib plus defactinib requires KRAS-mutated disease. Endometrial checkpoint selection increasingly depends on MMR/MSI status.
Testing therefore becomes part of launch excellence: a therapy can have strong efficacy yet underperform commercially if eligible patients are not routinely identified.
Drug Cost and Long Treatment Duration Remain Key Restraints
Checkpoint inhibitors, PARP drugs and ADCs carry considerably higher acquisition costs than generic platinum, taxane and hormonal therapies.
Long-duration maintenance increases cumulative expenditure and makes payer-defined biomarker selection increasingly important.
ADCs also introduce modality-specific monitoring burdens. Elahere, for example, has clinically important ocular toxicity requiring ophthalmic monitoring.
Tivdak similarly requires attention to ocular toxicity, peripheral neuropathy, and bleeding.
Gynecological Cancers Therapeutics Segment Analysis
Targeted Therapy and ADCs Lead with 36.8%
Targeted therapies and ADCs are estimated to account for 36.8% of global 2025 revenue, equal to around USD 6.77 billion.
This category includes PARP inhibitors, antiangiogenic drugs, lenvatinib-containing regimens, FRα-directed Elahere, tissue-factor-directed Tivdak, KRAS-selected Avmapki/Fakzynja, and other targeted products.
The category should continue expanding as ADCs move earlier in disease.
Elahere generated USD 690 million globally in 2025, and both sac-TMT and B7-H4-directed Mo-Rez now have large late-stage gynecological development programs.
Immunotherapy Accounts for 28.6%
Immunotherapy represents an estimated 28.6%, USD 5.26 billion.
The category has grown rapidly because checkpoint inhibitors have moved into first-line endometrial cancer, definitive cervical chemoradiotherapy, and now selected platinum-resistant ovarian cancer.
Immunotherapy should remain one of the fastest-growing classes through 2035, although future growth will increasingly depend on biomarker selection and combinations with ADCs rather than simple PD-1 monotherapy expansion.
Chemotherapy Represents 25.4%
Chemotherapy accounts for a 25.4% of 2025 revenue, or USD 4.67 billion.
Platinum-taxane regimens remain fundamental in ovarian and endometrial cancer, while cisplatin retains an important role in cervical chemoradiation.
Chemotherapy's percentage share is declining but its absolute market should remain sizeable because many immunotherapies and targeted drugs are added to, rather than substituted entirely for, chemotherapy.
Hormonal Therapy Accounts for 5.4%
Hormonal therapy represents 5.4%, around USD 994 million.
It is particularly relevant to selected hormone-sensitive endometrial cancers and low-grade gynecological tumors.
The segment is relatively mature and should expand more slowly than immunotherapy or ADCs.
Other therapies account for 3.8%.
Cancer Type Analysis
Ovarian, Fallopian Tube and Primary Peritoneal Cancer Lead with 41.5%
This combined segment is estimated to generate 41.5% of global therapeutic revenue in 2025, equivalent to USD 7.64 billion.
Its revenue leadership reflects high recurrence rates and repeated use of platinum chemotherapy, maintenance treatment, PARP inhibitors, bevacizumab, ADCs, and later-line targeted drugs.
The 2026 additions of pembrolizumab in PD-L1-positive platinum-resistant disease and relacorilant plus nab-paclitaxel further increase treatment intensity.
Endometrial and Uterine Cancer Represent 31.8%
Endometrial and uterine cancers account for an estimated 31.8% of revenue, USD 5.85 billion.
The segment is expanding rapidly because checkpoint therapy has moved into frontline advanced/recurrent treatment, while ADC development is accelerating.
The positive 2026 dMMR pembrolizumab monotherapy and sac-TMT Phase III results could create additional differentiated treatment pathways.
Cervical Cancer Accounts for 20.1%
Cervical cancer represents an estimated 20.1% of global therapeutic revenue, around USD 3.70 billion.
Revenue growth is increasingly driven by pembrolizumab moving into locally advanced curative-intent chemoradiation and Tivdak providing an ADC option after recurrent/metastatic chemotherapy.
The long-term pharmaceutical opportunity must be considered alongside HPV vaccination and screening, which WHO identifies as central tools for ultimately reducing disease incidence.
Vulvar and Vaginal Cancers Represent 3.8%
Vulvar and vaginal cancers collectively account for an estimated 3.8%, USD 699 million.
The markets remain relatively small and treatment continues to rely heavily on surgery, radiation and histology- or biomarker-adapted systemic therapy extrapolated from related cancers where appropriate.
Uterine Sarcoma and Other Gynecological Malignancies Represent 2.8%
Uterine sarcomas and other rare gynecological cancers contribute 2.8% of global therapeutic revenue, around USD 515 million.
These diseases should remain separately analyzed where possible because their biology, chemotherapy sensitivity and molecular treatment opportunities differ substantially from conventional endometrial carcinoma.
Gynecological Cancers Therapeutics Geographical Analysis
North America Leads with 42.4%
North America is estimated to account for 42.4% of global therapeutic revenue in 2025, equivalent to around USD 7.80 billion.
The existing DataM Intelligence page also identifies North America as the leading region.
The United States represents an estimated 37.2% of worldwide revenue, USD 6.84 billion.
The country's leadership reflects early regulatory access to major drug classes. During 2025-2026 alone, FDA approved KRAS-targeted Avmapki/Fakzynja for LGSOC, PD-L1-selected pembrolizumab for platinum-resistant ovarian cancer and relacorilant plus nab-paclitaxel for another platinum-resistant population.
Europe Accounts for 26.7%
Europe represents an estimated 26.7% of 2025 global revenue, or USD 4.91 billion.
Germany is at 5.2% of global revenue, the UK at 4.4%, France at 4.0%, Italy at 2.7%, and Spain at 2.4%.
European adoption increasingly centers on biomarker-defined products and national reimbursement decisions.
AbbVie, for example, moved Elahere into additional European commercial markets following its ovarian cancer approvals, while checkpoint-based endometrial treatment is now embedded across major oncology systems. AbbVie reported continued expansion of the Elahere franchise during 2025.
Asia-Pacific Is the Fastest-Growing Region
Asia-Pacific is estimated to generate 23.7% of global therapeutic revenue, around USD 4.36 billion, and is expected to be the fastest-growing major region.
China is at 6.2% of global revenue, Japan 4.7%, India 3.1%, South Korea 2.4%, and Australia 1.6%.
The region's patient burden is substantially larger than its revenue contribution for diseases such as cervical cancer. WHO continues to emphasize the disproportionate cervical-cancer burden in countries with weaker vaccination, screening, and treatment access.
Commercial access is also widening. In August 2025, GSK launched Jemperli and Zejula in India, bringing advanced endometrial immunotherapy and ovarian PARP maintenance into an important emerging oncology market.
Latin America Accounts for 4.4%
Latin America represents an estimated 4.4% of global revenue, USD 810 million.
Brazil is the largest country opportunity and is at 2.3% of global revenue.
Cervical cancer remains particularly relevant across the region, while the largest commercial constraints involve access to molecular testing, specialty oncology products and sustained maintenance therapy.
Middle East & Africa Represent 2.8%
Middle East & Africa account for an estimated 2.8% of market revenue, around USD 515 million.
Saudi Arabia, the UAE, Israel and South Africa represent the highest-value specialist markets.
The commercial gap between disease burden and pharmaceutical revenue is especially large for cervical cancer because many high-incidence countries continue to face limited access to screening and advanced oncology treatment. WHO's elimination strategy emphasizes vaccination, high-performance screening and adequate treatment coverage as interconnected priorities.
Competitive Landscape
Merck & Co.
Merck currently has one of the broadest gynecological oncology positions.
Pembrolizumab is established across endometrial and cervical cancer and entered PD-L1-positive platinum-resistant ovarian cancer in February 2026.
The company is also building a major ADC franchise around sacituzumab tirumotecan.
TroFuse-005 produced positive Phase III overall-survival and progression-free-survival results in previously treated endometrial cancer in May 2026, while TroFuse-033 is evaluating sac-TMT plus pembrolizumab in first-line pMMR endometrial maintenance.
GSK
GSK has a strategically focused women's cancer franchise through Jemperli/dostarlimab and Zejula/niraparib.
Dostarlimab's U.S. indication expanded in August 2024 to primary advanced or recurrent endometrial cancer regardless of MMR status when combined with carboplatin and paclitaxel.
GSK is additionally accelerating B7-H4-directed ADC mocertatug rezetecan, with five Phase III gynecological programs planned or initiated across ovarian and endometrial settings following positive 2026 early-stage data.
AstraZeneca
AstraZeneca remains a major ovarian-market participant through Lynparza/olaparib and has additional relevance through Imfinzi/durvalumab in dMMR endometrial cancer.
PARP maintenance continues to play a central role in biomarker-selected ovarian cancer, particularly BRCA-mutated and HRD-positive populations.
AbbVie
AbbVie has built a major ovarian ADC franchise through Elahere following its ImmunoGen acquisition.
Elahere generated USD 690 million in global 2025 revenue, and current clinical development aims to move mirvetuximab earlier into platinum-sensitive disease.
Pfizer / Genmab
Pfizer and Genmab participate in cervical cancer through Tivdak/tisotumab vedotin.
FDA granted traditional approval in April 2024 after the Phase III innovaTV 301 study demonstrated an overall-survival benefit over chemotherapy in recurrent/metastatic cervical cancer.
Verastem Oncology
Verastem created a new molecularly selected ovarian category with Avmapki/Fakzynja, the avutometinib-defactinib combination approved for previously treated KRAS-mutated recurrent low-grade serous ovarian cancer.
Corcept Therapeutics
Corcept entered gynecological oncology through Lifyorli/relacorilant.
FDA's March 2026 approval with nab-paclitaxel established glucocorticoid-receptor antagonism as a new treatment mechanism in platinum-resistant ovarian, fallopian tube and primary peritoneal cancer after prior bevacizumab.
Other important participants include Roche/Genentech, Eisai, Genmab, Daiichi Sankyo and a growing group of ADC and precision-oncology developers.
Recent Market Developments
- July 15, 2026: Merck announced positive Phase III results showing pembrolizumab monotherapy significantly improved progression-free survival versus platinum chemotherapy in first-line dMMR advanced/recurrent endometrial cancer, potentially supporting a future chemotherapy-free option.
- May 18, 2026: Merck announced that Phase III TroFuse-005 met both OS and PFS endpoints for sac-TMT versus chemotherapy in advanced/recurrent endometrial cancer following platinum and prior immunotherapy.
- April 12, 2026: GSK reported early BEHOLD-1 data for B7-H4 ADC mocertatug rezetecan, with a 62% confirmed response rate in platinum-resistant ovarian cancer and 67% in the small recurrent/advanced endometrial cohort; five Phase III programs are planned or underway.
- April 12, 2026: AbbVie reported a 62.7% response rate for Elahere plus carboplatin followed by Elahere continuation in FRα-expressing platinum-sensitive recurrent ovarian cancer.
- March 25, 2026: FDA approved Lifyorli/relacorilant plus nab-paclitaxel for previously treated platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer after prior bevacizumab.
- February 10, 2026: FDA approved pembrolizumab plus paclitaxel, with or without bevacizumab, for PD-L1-positive platinum-resistant ovarian/fallopian/peritoneal cancer after one or two prior systemic regimens.
- May 8, 2025: FDA granted accelerated approval to avutometinib plus defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer following previous systemic therapy.
Strategic Opportunity Areas Through 2035
ADC-Checkpoint Combinations
The largest emerging opportunity is combining antigen-directed ADC payload delivery with immune checkpoint blockade.
Sac-TMT plus pembrolizumab in pMMR endometrial cancer provides one of the clearest Phase III examples.
ADC Maintenance in Ovarian Cancer
The ADC market may expand beyond recurrent disease into maintenance after platinum therapy.
Merck and GSK both have large late-stage programs designed around ovarian maintenance, while AbbVie is developing Elahere further into platinum-sensitive disease.
Chemotherapy-Free dMMR Endometrial Treatment
Positive 2026 Phase III pembrolizumab monotherapy results create a route toward replacing platinum-doublet chemotherapy for selected dMMR patients rather than simply adding immunotherapy to it.
PD-L1 Testing in Ovarian Cancer
The February 2026 Keytruda approval makes PD-L1 a directly actionable biomarker in platinum-resistant ovarian cancer.
Commercial adoption will depend partly on integrating PD-L1 testing into an ovarian biomarker workflow already containing BRCA, HRD and FRα.
KRAS-Selected Low-Grade Serous Cancer
Avutometinib-defactinib demonstrates that LGSOC should be treated as a distinct molecular market rather than grouped entirely with high-grade epithelial ovarian cancer.
Further RAF/MEK, FAK and MAPK-pathway therapies may expand this niche.
Earlier-Line FRα Therapy
Elahere's next commercial step is earlier treatment in FRα-positive ovarian cancer.
Positive 2026 platinum-sensitive Phase II data support continued development beyond the current platinum-resistant indication.
Cervical-Cancer Immunotherapy Intensification
Pembrolizumab is already part of definitive chemoradiotherapy for stage III-IVA disease. Current NCI-listed Phase III research is testing whether adding induction chemotherapy before pembrolizumab-containing chemoradiation can improve outcomes further in high-risk locally advanced cervical cancer.
Buyer Value and Strategic Use of the Report
The refreshed analysis separates gynecological cancers according to the biomarkers and therapeutic mechanisms that now determine commercial value.
It replaces the current page's brand-by-brand segmentation with a clearer architecture covering immunotherapy, ADCs, PARP inhibition, antiangiogenic treatment, mutation-selected kinase therapy, chemotherapy and hormonal treatment.
The report also helps buyers map where the next growth comes from: chemo-free dMMR endometrial therapy, FRα and B7-H4 ADCs, TROP2 ADC combinations, PD-L1-selected ovarian immunotherapy, KRAS-positive LGSOC and earlier cervical immunotherapy.
Target Audience
Pharmaceutical and biotechnology companies, gynecologic oncology companies, ADC developers, immuno-oncology companies, PARP inhibitor manufacturers, companion-diagnostic companies, hospitals, comprehensive cancer centers, gynecologic oncologists, specialty pharmacies, genomic-testing companies, contract research organizations, healthcare investors, licensing teams and market-access organizations.
